ClinicalTrials.Veeva

Menu

Adult Patient Outcomes After Spine Surgery With Fibergraft BG Putty/Viper Prime

N

Nitin Agarwal

Status

Enrolling

Conditions

Spondylolisthesis, Lumbar Region
Spinal Trauma With Neurological Deficit
Degeneration of Lumbar Intervertebral Disc

Treatments

Device: Use of Viper Prime/Expedium system with Fibergraft BG Putty

Study type

Observational

Funder types

Other
Industry

Identifiers

NCT06704906
STUDY24040006

Details and patient eligibility

About

The Viper Prime/Expedium spine systems are intended to provide immobilization and stabilization of spinal segments in skeletally mature patients as an adjunct to fusion in the treatment of acute and chronic instabilities or deformities of the thoracolumbar and sacral spine. The Fibergraft Bioactive Glass (BG) is engineered to mimic the body's natural bone healing process. While previous studies have compared the use of Viper prime/Expedium spine system in minimally invasive and open surgeries, these studies did not specifically study the clinical and radiographic outcomes of patients who have received these implants in addition to Fibergraft. We aim to recruit patients with degenerative disc disease, spondylolisthesis, trauma, and/or pseudarthrosis who require spine surgery under standard of care and use these implants. We will then follow these patients for a duration of two years to report their clinical and radiographic outcomes to determine fusion, complication rate, and revision surgeries if any.

Enrollment

100 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Age ≥ 18 years
  2. Have a radiograph-based diagnosis of degenerative disc disease, spondylolisthesis, spinal trauma (i.e., fracture or dislocation), spinal stenosis, or deformity (i.e., scoliosis, kyphosis, and/or lordosis), spinal tumor, or pseudoarthrosis/failed fusion.
  3. Pathology of the thoracolumbar or sacral spine.
  4. Patients requiring fusion of 1-3 levels
  5. Patients receiving the surgery/devices as standard of care prescribed by the treating physician.

Exclusion criteria

  1. Patients < 18 years
  2. Patients with a cervical spine pathology
  3. Patients with spinal tumors
  4. Patients with bone density (DEXA) scores < 2.0 will be excluded.
  5. Current smokers and patients who quit smoking within 6 weeks prior to presentation will be excluded.
  6. Patients with a BMI > 40kg/m2
  7. Patients requiring fusion for more than 3 levels will be excluded

Trial contacts and locations

1

Loading...

Central trial contact

Nitin Agarwal, MD; Rida Mitha, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems